In this episode of ATTD 2026 Conference Catch-Up, we dive into Adjunct Therapies with Automated Insulin Delivery, featuring new clinical evidence on combining automated insulin delivery (AID) systems with adjunct pharmacological therapies to improve outcomes in Type 1 diabetes. As diabetes technology continues to evolve, researchers are exploring how therapies traditionally used in Type 2 diabetes-such as SGLT-2 inhibitors and GLP-1 receptor agonists-may complement automated insulin delivery systems to optimize glycemic control and potentially improve cardiometabolic outcomes. Join us as we summarize key takeaways from these thought-provoking presentations: • ADJUST T1D Study – Design and Glycemic Outcome – Dr. Viral N. Shah (United States of America) presents the study design and early glycemic outcomes of the ADJUST T1D trial, evaluating the impact of adjunct therapies alongside automated insulin delivery. • ADJUST T1D Study – Cardiovascular Outcomes – Dr. Janet K. Snell-Bergeon • Concurrent Use of AID with SGLT-2 – Dr. Ahmad Haidar• Real-Life Data on GLP Use in Type 1 Diabetes – Associate Professor Francisco J. Pasquel This episode is an essential listen for endocrinologists, diabetologists, clinical researchers, and healthcare professionals involved in diabetes technology looking to understand emerging strategies that combine automated insulin delivery with adjunct pharmacological therapies to enhance diabetes management. Enjoy the listen! This podcast was created using AI to provide a quick and insightful summary of an ATTD 2026 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information. ATTD 2026, the 19th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on 11–14 March 2026 in Barcelona. https://attd.kenes.com

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related